Published in final edited form as:

Eur J Med Chem. 2019 March 15; 166: 339–350. doi:10.1016/j.ejmech.2019.01.080.

Synthesis of 7-Benzylguanosine Cap Analogue Conjugates for eIF4E Targeted Degradation

Tanpreet Kaur, Arya Menon, and Amanda L. Garner*

Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, 1600 Huron Parkway, Ann Arbor, Michigan 48109, USA

Abstract

Eukaryotic translation initiation factor 4E (eIF4E) is a key player in the initiation of cap-dependent translation through recognition of the m⁷GpppX cap at the 5' terminus of coding mRNAs. As eIF4E overexpression has been observed in a number of human diseases, most notably cancer, targeting this oncogenic translation initiation factor has emerged as a promising strategy for the development of novel anti-cancer therapeutics. Toward this end, in the present study, we have rationally designed a series of Bn⁷GxP-based PROTACs for the targeted degradation of eIF4E. Herein we describe our synthetic efforts, in addition to biochemical and cellular characterization of these compounds.

Graphical Abstract

Keywords

eIF4E; PROTACs; m⁷G cap; cancer; proteasomal degradation

1. INTRODUCTION

Dysregulation of cap-dependent translation is a hallmark of many cancers [1,2,3]. Initiation of cap-dependent translation is dependent upon recognition of the m⁷GpppX cap (Figure

* algarner@umich.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

COMPETING INTERESTS:

The authors declare no competing interests.

SUPPORTING INFORMATION:

Spectra for all synthesized compounds.

1A) at the 5'-terminus of a mRNA by eukaryotic translation initiation factor 4E (eIF4E) [4]. Binding of eIF4E to the mRNA cap results in recruitment of the translation machinery, which then initiates protein synthesis at the transcript's start codon. eIF4E plays an essential role in controlling cellular growth and proliferation [5], and overexpression of this translation initiation factor is observed in many malignant cell lines and primary tumors, including breast [6], head and neck [7], and non-Hodgkin's lymphomas [8]. In previous literature reports, it has been shown that inhibition of eIF4E function slows tumor growth and induces apoptosis [9]. Thus, development of selective eIF4E inhibitors or degradation-inducing molecules could be a promising approach for the treatment of many cancers, in addition to providing valuable chemical tools for studying cap-dependent translation.

Molecular recognition of the m⁷GpppX cap by eIF4E involves cation- π interactions, in which Trp56 and Trp102 of eIF4E sandwich the positively-charged methylated guanine nucleobase of the cap (Figure 1B) [10]. This interaction is of utmost significance, as the binding affinity of m⁷GTP has been shown to be ~100-fold tighter than that of GTP itself (K_{ds} of 0.15 and 14 μ M, respectively) [10]. Based on the demonstrated importance of eIF4E in cellular and disease biology [3,11], many structure-activity relationship (SAR) campaigns have been carried out to rationally design m⁷G-based competitive inhibitors of eIF4E binding to capped mRNA (Figure 2) [12,13,14,15]. These studies have revealed that analogues containing benzyl or substituted benzyl groups at the 7-position (~10-fold enhancement in binding affinity) and at least one phosphate group are optimal inhibitors of eIF4E-cap binding [16,17,18]. In addition, efforts have been made to improve the cellular permeability of cap analogues through various pro-drug strategies (**4Ei-1,2,3** in Figure 2) [19,20,21].

Recently, PROteolysis-TArgeting Chimeras (PROTACs) [22,23] have emerged as a powerful alternative to traditional small molecule-based drug discovery approaches in that these bifunctional molecules can trigger intracellular protein degradation by marking proteins for proteasomal digestion [24,25,26,27,28]. In short, a small molecule ligand for the protein-of-interest is conjugated to an E3 ubiquitin ligase ligand, such as lenalidomide or VHL peptide, generating a novel two warhead probe [29] to enable the directed ubiquitination, and subsequent degradation, of the target protein [30]. To date, this strategy has been successfully extended to BET family [25,31,32,33], Sirtuin 2 [34], CDK9 [35], Skp1-cullin-F-box [36], BCR-ABL [37] and ERR α proteins [38]. Thus, based on the previous successes of m⁷G cap analogues as inhibitors of eIF4E, we became interested in developing PROTACs based upon this scaffold for the targeted proteasomal degradation of eIF4E [14,39,40]. To this end, **4Ei-1** has been previously shown to induce eIF4E proteasomal degradation in a dose-dependent manner; however, high concentrations (100-500 μ M) of the compound were required to see an effect [41]. By using a PROTAC strategy, our goal was to achieve this biological effect with lower concentrations due to the catalytic nature of these conjugates, thereby, providing in-roads toward the development of these molecules for therapeutic applications. Herein we disclose our synthetic efforts toward cap-competitive eIF4E-targeted PROTACs and their preliminary *in vitro* and cellular characterization.

2. RESULTS AND DISCUSSION

2.1. Assessing eIF4E as a Candidate for PROTAC Development

Little is known about the endogenous turnover of the eIF4E protein [42,43,44]. To date, only the C-terminus of Hsc-70 interacting protein (CHIP) and cellular inhibitor of apoptosis protein-1 (cIAP1) E3 ligases have been implicated in eIF4E ubiquitination and degradation under conditions of cellular stress [43,44]. eIF4E contains 16 total lysine residues, 13 of which have been shown to be solvent accessible via X-ray crystallography (Lys21, 36, 49, 52, 54, 65, 106, 108, 119, 159, 162, 192, 212) [45] for possible ubiquitination. Notably, several of these residues are within 15 Å of the cap-binding pocket (Figure 1B) [45], which is an essential requirement for the use of PROTAC technology [46]. Thus, we were encouraged that eIF4E degradation could be induced with appropriate Bn⁷GxP-based PROTAC design.

2.2. Design and Synthesis of GMP-based PROTACs

As an initial PROTAC design strategy, we generated a small library of guanosine monophosphate (GMP) derivatives conjugated to lenalidomide (**1**), a ligand for the well-known E3 ligase, cereblon [47,48]. GMP was chosen as the Bn⁷GxP scaffold based on its successful use in previously reported inhibitors of eIF4E (Figure 2) [21,39,40,49]. The synthetic route is shown in Scheme 1 and began with HATU-mediated coupling of **1** with Boc-6-aminohexanoic acid to form Boc-protected amide **2** in 89% yield, followed by Boc deprotection in quantitative yield. The unmasked free amine **3** was then subjected to coupling with GMP disodium salt to provide GMP-lenalidomide conjugate **4** in 31% yield [18,50]. The low reaction yield for this step was due to solvent incompatibility between the hydrophobic lenalidomide derivative **3** and hydrophilic GMP. Alkylation at the 7-position with benzyl bromide or 4-fluorobenzyl bromide [18,51] yielded Bn⁷GMP PROTACs **5a** and **5b** in 4% and 29% yields, respectively. 4-Fluorobenzyl substitution was also examined, as this modification was previously shown to further enhance binding affinity to eIF4E [10]. Again, yields were low due to poor solubility.

2.3. Design and Synthesis of Bioisosteres of GMP-based PROTACs

Aryl sulfamates have previously been reported as bioisosteres of phosphate groups [51]. Thus, we were also interested in the synthesis of such non-hydrolyzable Bn⁷GMP-based PROTACs. The synthesis, which is shown in Scheme 2, began with TBS protection of guanosine to yield **6** in 70% yield. Sulfamoylation at the 5' position was then carried out using sulfamoyl chloride [51] generated *in situ* from formic acid and chlorosulfonyl isocyanate [51] to yield **7** in 95% yield. Coupling with *N*-hydroxysuccinic (NHS) ester **8** in the presence of DBU, followed by deprotection of the tert-butyl protecting group resulted in **10**. Interestingly, conjugation of the free acid of this compound with lenalidomide (**1**) under HATU- or PyBrOP-mediated coupling conditions did not yield the desired product. Since we speculated that this may be due to the weak basicity of **1**, we utilized the lenalidomide derivative **3**, which resulted in the formation of **11** in 40% yield. Subsequent deprotection of the TBS groups with TBAF and alkylation at the 7-position produced the target PROTACs **13a** and **13b** in 45% and 55% yields, respectively. Yields for the alkylation of sulfamate

derivative **12** were better than that of the corresponding GMP due to its enhanced solubility in DMSO.

2.4. Biochemical Characterization of GMP-based PROTACs

To test the ability of the Bn⁷GMP-based PROTACs to bind to eIF4E and compete with the m⁷GpppX cap, we developed an *in vitro* cap competition assay (Figure 3A). In this assay, cell lysate is first incubated with m⁷GxP (GMP or GDP) agarose resin [52] to enable the affinity purification of eIF4E. The preparation of this resin is shown in Figure 3B and uses aniline-catalyzed reductive amination chemistry for chemical conjugation. Resin-immobilized eIF4E is then incubated with compounds, such as m⁷GxP or a PROTAC. If the compound is active, eIF4E will be competed off the resin; however, if there is no inhibitory activity, eIF4E will be retained and detected by Western blot analysis.

Each of the synthesized Bn⁷GMP-based PROTACs (**5a**, **5b**, **13a**, **13b**), in addition to the GMP-lenalidomide conjugates **4** and **12**, were tested in the m⁷GMP cap competition assay using m⁷GMP as a positive control. As shown in Figure 4, upon treatment of eIF4E immobilized from HEK293 cell lysate, negligible inhibition was observed with either the Bn⁷GMP- or sulfamate-based PROTACs in comparison to the control. No inhibition with the GMP derivatives was observed as expected. We hypothesize that this is due to the decreased or absent negative charge on the phosphoramidate and sulfamate moieties, respectively, as a similar effect has been observed with other GxP-binding proteins [53].

2.5. Design and Synthesis of GDP-based PROTACs

As m⁷GDP has been shown to exhibit 50-fold greater inhibitory activity against eIF4E-cap binding as compared to m⁷GMP [17], we next synthesized Bn⁷GDP-based PROTACs with hopes that they would exhibit activity in the cap competition assay. In this case, we chose to incorporate both lenalidomide and VHL ligand conjugates as part of our PROTAC design, in addition to varying linker lengths, which has been shown to play a crucial role in the success of this approach [26],[54].

For the lenalidomide conjugates, we followed a similar synthetic route to those used for the GMP compounds (Scheme 3). The synthesis began with HATU-mediated coupling of lenalidomide (**1**) with alkyl and PEG linkers to form Boc-protected amides **14–16** in 18–89% yields. In case of the PEG7 analogue **16**, we suspect that the observed low yield was due to its aggregation propensity. Following deprotection, the unmasked free amines **17–19** were subjected to EDCI-mediated coupling with the sodium salt of GDP to yield conjugates **20–22** in 32–35% yields [18,50]. Alkylation was performed with benzyl or 4-fluorobenzyl bromide [18,51], and resulted in Bn⁷GDP-based PROTACs **23–25** in 9–20% yields. Low yields were observed due to both poor solubility and minor hydrolysis of GDP.

The VHL ligand (**26**) was conjugated to GDP through a similar synthetic route (Scheme 4). In this case, however, only the alkyl linker was used. HATU-mediated coupling of **26** with Boc-6-aminohexanoic acid to yield Boc-protected amide **27** in 75% yield. After deprotection, amine **28** was conjugated to GDP via known EDC coupling [21], which produced GDP-VHL conjugate **29** in 32% yield. Subsequent alkylation [18,51] then

generated the target PROTACs **30a** and **30b** in 11% and 41% yields, respectively. Similar challenges with solubility and stability were encountered.

2.6. Biochemical Characterization of GDP-based PROTACs:

Each of the synthesized GDP- (**20–22** and **29**) and Bn⁷GDP-based PROTACs (**23–25** and **30**) was tested for eIF4E inhibitory activity in the m⁷GDP cap competition assay (Figure 3A), in this case, using m⁷GDP as a positive control. To our delight, each of the Bn⁷GDP conjugates was found to be active (Figure 5A), while the GDP derivatives showed no activity as expected. Within the alkyl linker series (Figure 5A, top), no observable inhibitory activity differences were observed between the lenalidomide and VHL conjugates. Interestingly, however, the PEG3 lenalidomide (**21**, **24a-b**) PROTAC showed enhanced activity in comparison the PEG7 analogues (**22**, **25a-b**) (Figure 5A, bottom). Inhibition of eIF4E-cap binding was also found to be dose-dependent for each of the PROTACs, and representative data for **23a** is shown in Figure 5B.

2.7. Cellular Characterization of GDP-based PROTACs:

Encouraged by the promising biochemical data obtained with the Bn⁷GDP-based PROTACs, we proceeded to cellular assays to determine if these compounds were able to induce the proteasomal degradation of eIF4E. MDA-MB-231 breast cancer cells were treated with varying concentrations (25–200 μ M) of PROTACs for 24–72 h. Unfortunately, decreased eIF4E protein levels were not detected with any of the conjugates (data not shown). Because we suspected that low cellular permeability may be a problem, we next tested the PROTACs in K562 cells, which have been found to more readily uptake purine nucleotides [55]. Across a similar set of conditions, again we saw no intracellular degradation of eIF4E (representative data in Figure 6). Thus, we hypothesize that the permeability of these compounds is still low, as has been observed with other cap analogues [14,18,21] or that ternary complex formation between eIF4E and the E3 ligase is not possible with the designed molecules. Future efforts should be focused on examining additional linkers, as this has been shown to play a crucial role in successful PROTAC design, in addition to the exploration of additional E3 ligase ligands, such as those for cIAP and MDM2 [26, 54].

3. CONCLUSION

In conclusion, we have synthesized a library of Bn⁷GxP-based PROTACs for the targeted degradation of eIF4E, the m⁷GpppX cap-binding translation initiation factor. The targeting of aberrant eIF4E activity with m⁷G cap analogues is rich with history [2,11,13], yet continues to be plagued with issues of cellular permeability due the necessity for nucleotide-based scaffolds [18,39,40]. Unfortunately, our efforts described herein were similarly unsuccessful in translating to cellular assays. While pro-drugs have been developed (Figure 2), the requirement for high micromolar concentrations in cells dampens enthusiasm for clinical development [19,20, 41]. Thus, future efforts in targeting eIF4E should focus on the discovery of non-nucleotide small molecule competitive antagonists of cap binding or inhibiting its protein-protein interactions, which are also crucial for its activity in initiating cap-dependent translation [1,3].

4. EXPERIMENTAL

4.1. General Materials and Methods:

Lenalidomide (**1**) was purchased from AstaTech and used as received. VHL ligand (**26**) was purchased from Abosyn and used as received. GMP and GDP were purchased from ChemImpex and used as received. All solvents and reagents were used without further purification. Yields refer to chromatographically and spectroscopically (^1H NMR) homogeneous materials, unless otherwise stated. Reactions were monitored by thin-layer chromatography (TLC) carried out on 0.25-mm SiliCycle silica gel plates (60F-254) using UV-light (254 nm). Flash chromatography was performed using SiliaFlash P60 silica gel. Analytical RP-HPLC was performed using an Agilent 1260 Infinity HPLC equipped with a ZORBAX Eclipse XDB-C18 column (4.6×150 mm; $5\ \mu\text{m}$) at a flow rate of 1 mL/min, with detection at 214 and 254 nm. Semi-preparative HPLC was carried out on Agilent 1260 Infinity HPLC equipped with a PrepHT XDB-C18 column (21.2×150 mm; $5\ \mu\text{m}$) at a flow rate of 18 mL/min using 95% water as a mobile phase and detection at 254 nm and 214 nm. NMR spectra were performed on a 300 MHz Bruker instrument and calibrated using a solvent peak as an internal reference. Spectra were processed using MestReNova software. Mass spectrometry (HRMS) was performed using an Agilent 6520 Accurate-Mass Q-TOF LC/MS spectrometer using ESI ionization with less than 5-ppm error for all HRMS analyses.

4.2 General procedure A:

Boc-protected acids (1.1 mmol, 1.1 equiv) were added to a stirring solution of lenalidomide/VHL ligand (1.0 equiv), HATU (1.2 equiv) and DIPEA (2.0 equiv) in dry DMF (0.22 M) at 25 °C. The reaction mixture was allowed to stir at 25 °C for 12 h. Upon completion of the reaction as determined via TLC, the mixture was acidified with dilute HCl (5%, 5 mL) and extracted with EtOAc (3 $\times$). The organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure in vacuo. The crude reaction mixture was purified by silica gel chromatography using EtOAc in hexanes (30–100% EtOAc) to yield the desired products as a white solid in 18–56% yields.

4.3 General procedure B:

To an ice-cold stirring solution of Boc-protected derivatives (1 equiv) in DCM (5 mL) was added trifluoroacetic acid (TFA) (5 mL). The reaction mixture was warmed to 25 °C and stirred for an additional 2 h. Upon completion of the reaction, the solvent was evaporated under reduced pressure in vacuo. The crude product was dried further under high vacuum for 4 h and was used directly for the next step.

4.4 General procedure C:

To a stirring solution of GMP or GDP sodium salt (1.0 equiv) in water at pH 7.2 (0.06 M) was added *N*-methyl morpholine (10 equiv), EDCI. HCl (5 equiv), and free amine derivatives (1.0 equiv) in DMSO (0.06 M). The reaction mixture was stirred overnight at 25 °C. Upon completion, the mixture was diluted with water and purified by semi-

preparative HPLC (2–20% acetonitrile in water). Product-containing fractions were pooled and lyophilized to dryness to yield the desired products as white solids.

4.5 General procedure D:

To a stirring solution of guanosine analogues (1.0 equiv) in dry DMSO (0.006 M) was added alkyl bromide (10 equiv). The reaction mixture was stirred overnight at 25 °C. Upon completion, the mixture was diluted with water and extracted with diethyl ether (3×). The combined water layers were lyophilized and purified by semi-preparative HPLC (2–40% acetonitrile in water). Product containing fractions were pooled and lyophilized to dryness to yield the Bn⁷GxP analogues as white solids.

4.6 Compound characterization:

tert-Butyl(6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-6-oxohexyl) carbamate (2).—General procedure A, 89% yield. *R_f* 0.40 (EtOAc). ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.01 (s, 1H), 9.78 (s, 1H), 7.81 (d, *J* = 7.2 Hz, 1H), 7.47 (d, *J* = 11.7 Hz, 2H), 6.75 (d, *J* = 5.4 Hz, 1H), 5.13 (d, *J* = 18.4 Hz, 1H), 4.43–4.27 (m, 2H), 2.89 (d, *J* = 24.4 Hz, 4H), 2.35 (s, 3H), 2.01 (dd, *J* = 9.7, 4.5 Hz, 1H), 1.58 (d, *J* = 14.8 Hz, 2H), 1.42–1.36 (m, 2H), 1.34 (s, 9H), 1.27 (p, *J* = 7.5, 6.9 Hz, 2H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 173.28, 171.78, 171.49, 168.29, 162.74, 156.03, 134.26, 134.12, 133.09, 129.02, 125.67, 119.39, 77.75, 52.00, 46.97, 40.44, 40.22, 36.22, 31.66, 29.76, 28.71, 26.45, 25.30, 23.09. **HRMS (ESI-TOF)** *m/z* calcd for C₂₄H₃₂N₄O₆ [M + H]⁺ 473.2400, found 473.2421.

6-Amino-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)hexanamide (3).—General procedure B, 100% yield. *R_f* 0.2 (EtOAc). **HRMS (ESI-TOF)** *m/z* calcd for C₁₉H₂₄N₄O₄ [M + H]⁺ 373.1876, found 373.1882.

((2S,3R,4S,5S)-5-(2-Amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methylhydrogen(6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-6-oxohexyl)phosphoramidate (4).—General procedure C, 31% yield. ¹H NMR (500 MHz, D₂O) δ 7.94 (t, *J* = 3.5 Hz, 1H), 7.57–7.52 (m, 1H), 7.46–7.34 (m, 2H), 5.73–5.63 (m, 1H), 5.06–4.96 (m, 1H), 4.57–4.49 (m, 1H), 4.35–4.29 (m, 1H), 4.25–4.13 (m, 3H), 3.93–3.82 (m, 2H), 3.01 (d, *J* = 50.7 Hz, 5H), 2.87–2.75 (m, 2H), 2.61 (d, *J* = 3.2 Hz, 2H), 2.44–2.34 (m, 1H), 2.26–2.16 (m, 3H), 1.75 (d, *J* = 6.9 Hz, 2H), 1.41 (d, *J* = 5.4 Hz, 2H), 1.30 (d, *J* = 3.2 Hz, 2H), 1.19–1.00 (m, 3H), 0.93 (d, *J* = 17.5 Hz, 2H). ³¹P NMR (202 MHz, D₂O) δ 9.18 (d, *J* = 6.1 Hz). **HRMS (ESI-TOF)** *m/z* calcd for C₂₉H₃₅N₉O₁₁P [M – H][–] 716.2194, found 716.2234.

2-Amino-7-benzyl-9-((2S,3S,4R,5S)-5-((((6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-6-oxohexyl)amino)(hydroxy)phosphoryl)oxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-7-ium (5a).—General procedure D, 4% yield. **HRMS (ESI-TOF)** *m/z* calcd for C₃₆H₄₁N₉O₁₁P [M – H][–] 806.2658, found 806.2683.

2-Amino-9-((2S,3S,4R,5S)-5-((((6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-6-oxohexyl)amino)(hydroxy)phosphoryl)oxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-7-(4-fluorobenzyl)-6-oxo-6,9-dihydro-1H-purin-7-ium (5b).—General procedure D, 29% yield. **HRMS (ESI-TOF)** m/z calcd for $C_{36}H_{40}FN_9O_{11}P$ $[M - H]^-$ 824.2563, found 824.2593.

2-Amino-9-((2R,3R,4R,5R)-3,4-bis((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one (6).—To a stirring solution of guanosine (10 g, 35.3 mmol, 1.0 equiv) and imidazole (19 g, 283 mmol, 8 equiv) in dry DMF (70 mL) was added TBSCl (21.2 g, 142 mmol, 4 equiv) under nitrogen atmosphere. The resulting solution was stirred overnight at 25 °C. The reaction mixture was diluted with water (200 mL) and extracted with DCM (3 × 50 mL). The combined DCM layers were washed with sat. aq. NH_4Cl (1 × 25 mL), water (1 × 50 mL), dried over sodium sulfate and concentrated under vacuum. The resultant white solid was suspended in 80% acetic acid (300 mL) and the reaction mixture was heated at 60 °C for 12 h. Upon completion, the solvent was evaporated under vacuum and the crude product was purified by silica gel column chromatography using DCM/methanol (0–20% methanol) to yield **6** as a white solid (12.7 g, 70% yield). **1H NMR** (500 MHz, $DMSO-d_6$) δ 10.62 (s, 1H), 7.98 (s, 1H), 6.44 (s, 3H), 5.73 (d, $J = 7.3$ Hz, 1H), 5.29–5.19 (m, 2H), 4.69 (dd, $J = 7.3, 4.5$ Hz, 1H), 4.27–4.18 (m, 1H), 3.92 (ddd, $J = 5.0, 3.5, 1.3$ Hz, 1H), 3.67 (dt, $J = 11.9, 5.2$ Hz, 1H), 3.56 (ddd, $J = 11.9, 5.9, 3.5$ Hz, 1H), 0.91 (s, 10H), 0.73 (s, 9H), 0.11 (d, $J = 8.3$ Hz, 6H), –0.09 (s, 3H), –0.31 (s, 3H). **^{13}C NMR** (126 MHz, $DMSO-d_6$) δ 157.10, 154.09, 151.87, 136.14, 117.18, 87.17, 86.16, 75.43, 73.57, 61.71, 40.48, 40.31, 40.14, 39.97, 39.81, 39.64, 39.47, 26.26, 26.20, 25.96, 18.26, 18.02, –2.74, –4.21, –4.30, –5.09. **HRMS (ESI-TOF)** m/z calcd for $C_{22}H_{42}N_5O_5Si_2$ $[M + H]^+$ 512.2724, found 512.2724.

Sulfamoyl chloride [51].—To an ice-cold stirring solution of chlorosulfonyl isocyanate (600 μ L, 6.85 mmole, 1 equiv.), formic acid (285.5 μ L, 6.85 mmole, 1 equiv.) was added drop-wise. After 10 min, the reaction mixture was warmed to 25 °C and stirred for 1 h. It was used directly for the synthesis of **7**.

((2R,3R,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3,4-bis((tert-butyldimethylsilyl)oxy)tetrahydrofuran-2-yl)methyl sulfamate (7).—To an ice-cold stirring solution of **6** (1.5 g, 3.0 mmol, 1.0 equiv) in dry DMF (10 mL) was added sulfamoyl chloride (345 mg, 3.3 mmol, 1.1 equiv) under nitrogen atmosphere. The resulting solution was warmed to 25 °C and stirred for 1 h. Triethyl amine (3 mL) was then added and the reaction was stirred for 10 min. The reaction mixture was cooled to 0 °C, quenched with methanol (5 mL) and concentrated under vacuum. The reaction mixture was dissolved in ethyl acetate (50 mL), washed with brine and water (200 mL), dried over sodium sulfate and concentrated under vacuum. The crude reaction mixture was purified by silica gel column chromatography using DCM/methanol (0–20% methanol with 0.1% TEA) to yield **7** as a white solid (1.64 g, 95% yield). **1H NMR** (500 MHz, $DMSO-d_6$) δ 10.66 (d, $J = 6.0$ Hz, 1H), 7.89 (s, 1H), 7.63 (s, 2H), 6.43 (s, 2H), 5.74 (d, $J = 7.4$ Hz, 1H), 4.76 (dd, $J = 7.3, 4.4$ Hz, 1H), 4.29 (dd, $J = 11.3, 5.2$ Hz, 1H), 4.26–4.19 (m, 2H), 4.13 (t, $J = 5.2$ Hz, 1H), 0.90 (s,

9H), 0.71 (s, 9H), 0.11 (d, $J = 10.5$ Hz, 6H), -0.08 (s, 3H), -0.30 (s, 3H). ^{13}C NMR (126 MHz, DMSO- d_6) δ 157.14, 154.13, 151.98, 136.09, 117.25, 86.26, 83.39, 74.49, 73.12, 68.50, 40.46, 40.30, 40.13, 39.96, 39.80, 39.63, 39.46, 26.16, 25.93, 18.19, 17.97, -4.28 , -4.30 , -4.40 , -5.09 . HRMS (ESI-TOF) m/z calcd for $\text{C}_{22}\text{H}_{43}\text{N}_6\text{O}_7\text{SSi}_2$ $[\text{M} + \text{H}]^+$ 591.2452 found 591.2460.

tert-butyl-4-((((2R,3R,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3,4-bis((tertbutyldimethylsilyl)oxy)tetrahydrofuran-2-yl)methoxy)sulfonyl)amino)-4-oxobutanoate (9).—To a stirring solution of 4-(*tert*-butoxy)-4-oxobutanoic acid (693 mg, 3.0 mmol, 1 equiv) in DCM (5.0 mL), DIPEA (1.04 mL, 6.0 mmol, 2 equiv), and *N*-hydroxysuccinimide (379.5 mg, 3.3 mmol, 1.1 equiv) was added HATU (1.25 g, 3.3 mmol, 1.1 equiv). The resulting solution was stirred under argon at 25 °C for 4 h. Upon completion of reaction, sat. brine (20 mL) was added and the aqueous layer was extracted with DCM. The combined DCM layers were dried over anhydrous sodium sulfate and concentrated under vacuum. The flask was left under high vacuum for 2 h and crude **8** was used without further purification. **8** (1.7 g, 3.0 mmol, 1.5 equiv) and compound **7** (1.8 g, 2.0 mmol, 1.0 equiv) was re-dissolved in dry DMF (5 mL) and was cooled at 0 °C. DBU (492 μL , 3.3 mmol, 1.1 equiv) was added and the reaction mixture was stirred at 25 °C overnight. Next, the reaction mixture was dried under high vacuum and purified by silica gel column chromatography using DCM/methanol (0–20% methanol) to yield **9** as a white solid (939 mg, 42% yield). ^1H NMR (500 MHz, DMSO- d_6) δ 7.92 (d, $J = 9.5$ Hz, 1H), 7.76 (s, 1H), 6.49 (s, 2H), 5.75 (d, $J = 7.4$ Hz, 1H), 4.77 (dd, $J = 7.2, 4.7$ Hz, 1H), 4.54–4.42 (m, 2H), 4.40–4.32 (m, 1H), 4.21 (dd, $J = 21.1, 4.7$ Hz, 2H), 4.13 (s, 1H), 2.49–2.40 (m, 3H), 1.38 (d, $J = 5.8$ Hz, 9H), 0.91 (s, 9H), 0.72 (s, 9H), 0.11 (s, 7H), -0.07 (s, 3H), -0.30 (s, 3H). ^{13}C NMR (126 MHz, DMSO- d_6) δ 171.87, 171.56, 157.19, 154.13, 152.00, 136.10, 117.17, 92.79, 86.18, 83.29, 82.85, 80.28, 77.40, 74.47, 73.20, 72.14, 70.95, 53.56, 40.48, 40.31, 40.15, 39.98, 39.81, 39.65, 39.48, 31.39, 29.78, 28.22, 28.14, 26.21, 26.15, 25.92, 25.67, 18.30, 18.19, 18.11, 17.95, -4.00 , -4.23 , -4.32 , -4.41 , -4.45 , -4.51 , -5.17 . HRMS (ESI-TOF) m/z calcd for $\text{C}_{30}\text{H}_{54}\text{N}_6\text{O}_{10}\text{SSi}_2$ $[\text{M} + \text{H}]^+$ 747.3239 found 747.3232.

4-((((2R,3R,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3,4-bis((tert-butyl)dimethylsilyl)oxy)tetrahydrofuran-2-yl)methoxy)sulfonyl)amino)-4-oxobutanoic acid (10).—Compound **9** (185 mg, 0.26 mmol) was dissolved in DCM/TFA/ Et_3SiH (2:1:0.1, 2 mL) and stirred for 2 h. The solution was concentrated to dryness and left on high vacuum for 2 h. It was used directly for next reaction (90% yield). HRMS (ESI-TOF) m/z calcd for $\text{C}_{26}\text{H}_{47}\text{N}_6\text{O}_{10}\text{SSi}_2$ $[\text{M} + \text{H}]^+$ 691.2613 found 691.2610.

((2R,3R,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3,4-bis((tert-butyl)dimethylsilyl)oxy)tetrahydrofuran-2-yl)methyl(4-((6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-6-oxohexyl)amino)-4-oxobutanoyl)sulfamate (11).—To a stirring solution of **10** (100 mg, 0.26 mmol, 1 equiv), **3** (185 mg, 0.26 mmol, 1 equiv) and NMM (289 μL , 2.6 mmol, 10 equiv) in DMSO/water at pH 7.0 (6 mL, 1:1) was added EDC.HCl (248.3 mg, 1.3 mmol, 5 equiv). The resultant solution was stirred overnight at 25 °C. The reaction mixture was diluted with

water and purified by semi-preparative HPLC (20–80% acetonitrile in water) to yield **11** as a white solid (112 mg, 40%). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 10.99 (s, 1H), 10.67 (s, 1H), 9.73 (s, 1H), 7.89 (s, 1H), 7.85 (q, *J* = 5.6 Hz, 1H), 7.81–7.78 (m, 1H), 7.51–7.41 (m, 2H), 6.43 (s, 2H), 5.73 (d, *J* = 7.5 Hz, 1H), 5.12 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.73 (dd, *J* = 7.4, 4.5 Hz, 1H), 4.50 (dd, *J* = 10.9, 5.3 Hz, 1H), 4.40 (dd, *J* = 10.7, 4.7 Hz, 2H), 4.37–4.27 (m, 2H), 4.21 (d, *J* = 4.7 Hz, 1H), 4.11 (t, *J* = 5.2 Hz, 1H), 3.03 (d, *J* = 6.6 Hz, 2H), 2.91 (dd, *J* = 13.5, 5.3 Hz, 2H), 2.58 (d, *J* = 16.8 Hz, 1H), 2.50–2.46 (m, 3H), 2.33 (q, *J* = 7.1, 6.6 Hz, 5H), 2.03–1.96 (m, 1H), 1.57 (p, *J* = 7.5 Hz, 2H), 1.43–1.35 (m, 2H), 1.32–1.24 (m, 2H), 0.88 (s, 9H), 0.69 (s, 9H), 0.09 (d, *J* = 9.9 Hz, 6H), –0.09 (s, 3H), –0.32 (s, 3H). **¹³C NMR** (126 MHz, DMSO-*d*₆) δ 173.28, 171.72, 171.56, 171.49, 170.84, 168.27, 157.14, 154.15, 152.00, 135.99, 134.25, 134.08, 133.10, 129.02, 125.64, 119.39, 117.18, 86.12, 83.12, 74.46, 73.11, 71.35, 51.98, 46.93, 40.87, 40.46, 40.29, 40.13, 39.96, 39.79, 39.62, 39.46, 38.99, 36.20, 31.66, 31.36, 29.64, 29.36, 26.59, 26.20, 26.14, 25.90, 25.28, 23.09, 18.16, 17.94, –4.32, –4.35, –4.46, –5.19. **HRMS (ESI-TOF)** *m/z* calcd for C₄₅H₆₈N₁₀O₁₃SSi₂ [M + H]⁺ 1045.4305 found 1045.4295.

((2R,3S,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl(4-((6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-6-oxo hexyl)amino)-4-oxobutanoyl)sulfamate (12).—

To an ice-cold stirring solution of **11** (60 mg, 0.06 mmol, 1 equiv) in THF (3.0 mL) was added 1M TBAF (171 μL, 0.2 mmol, 3 equiv). The resultant solution was warmed to 25 °C and stirring was continued for 5 min. The reaction was diluted with methanol and concentrated under vacuum. The crude residue was purified by silica gel chromatography (20% methanol in DCM) followed by further purification via semi-preparative HPLC (20–80% acetonitrile in water) to yield **12** as white solid (35 mg, 71%). **¹H NMR** (500 MHz, DMSO-*d*₆) δ 11.00 (s, 1H), 9.82 (s, 2H), 8.36 (s, 2H), 7.90 (s, 1H), 7.86–7.75 (m, 3H), 7.46 (d, *J* = 6.8 Hz, 2H), 6.82 (s, 2H), 5.68 (d, *J* = 6.5 Hz, 1H), 5.14–5.06 (m, 1H), 4.50–4.29 (m, 5H), 4.12–3.90 (m, 5H), 3.01 (d, *J* = 6.5 Hz, 3H), 2.93–2.83 (m, 2H), 2.64–2.56 (m, 1H), 2.48 (s, 2H), 2.36 (dt, *J* = 22.2, 5.9 Hz, 4H), 2.04–1.96 (m, 1H), 1.55 (s, 9H), 1.52 (d, *J* = 7.7 Hz, 8H), 1.44–1.35 (m, 2H). **¹³C NMR** (126 MHz, DMSO-*d*₆) δ 177.14, 173.28, 172.49, 171.90, 171.46, 168.29, 165.79, 157.42, 154.49, 151.97, 135.87, 134.35, 134.11, 133.09, 128.96, 125.60, 119.24, 116.92, 86.69, 83.14, 73.87, 71.40, 67.52, 57.99, 52.06, 47.07, 38.79, 36.22, 35.32, 32.64, 31.66, 29.36, 26.53, 25.32, 23.05. **HRMS (ESI-TOF)** *m/z* calcd for C₃₃H₄₁N₁₀O₁₃S [M + H]⁺ 817.2575 found 817.2558.

2-Amino-7-benzyl-9-((2R,3R,4S,5R)-5-(((N-(4-((6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-6-oxohexyl)amino)-4-oxobutanoyl)sulfamoyl)oxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-7-ium (13a).—General procedure D, 45%. **¹H NMR** (500 MHz, DMSO-*d*₆) δ 10.99 (s, 1H), 10.12 (d, *J* = 66.0 Hz, 1H), 9.73 (s, 1H), 7.85–7.21 (m, 9H), 5.85 (d, *J* = 25.5 Hz, 1H), 5.61 (t, *J* = 13.1 Hz, 3H), 5.47 (s, 1H), 5.11 (d, *J* = 12.5 Hz, 2H), 4.64–3.75 (m, 11H), 3.08–2.83 (m, 2H), 2.59 (d, *J* = 16.3 Hz, 1H), 2.41–2.19 (m, 6H), 2.04–1.89 (m, 1H), 1.63–1.19 (m, 7H). **HRMS (ESI-TOF)** *m/z* calcd for C₄₀H₄₅N₁₀O₁₃S [M – H][–] 905.2883 found 905.2874.

2-Amino-9-((2R,3R,4S,5R)-5-(((N-(4-((6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-6-oxohexyl)amino)-4-oxobutanoyl)sulfamoyl)oxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-7-(4-fluorobenzyl)-6-oxo-6,9-dihydro-1H-purin-7-ium (13b).—General procedure D, 55%. ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.01 (s, 1H), 10.18 (s, 1H), 9.75 (s, 2H), 8.16 (s, 1H), 7.84–7.80 (m, 1H), 7.78–7.69 (m, 4H), 7.50 (d, *J* = 6.4 Hz, 2H), 7.17 (t, *J* = 8.8 Hz, 3H), 5.83 (s, 1H), 5.71–5.52 (m, 3H), 5.13 (d, *J* = 18.4 Hz, 2H), 4.43–4.30 (m, 4H), 4.21 (s, 1H), 4.12 (d, *J* = 17.4 Hz, 2H), 4.02 (d, *J* = 10.9 Hz, 1H), 3.19–3.12 (m, 2H), 2.94 (d, *J* = 35.4 Hz, 3H), 2.61 (d, *J* = 18.0 Hz, 2H), 2.41–2.20 (m, 9H), 2.10–1.98 (m, 2H). ¹⁹F NMR (470 MHz, DMSO-*d*₆) δ –148.28, –148.33. HRMS (ESI-TOF) *m/z* calcd for C₄₀H₄₆FN₁₀O₁₃S [M + H]⁺ 925.2945 found 925.2951.

tert-Butyl(2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-3-oxopropoxy)ethoxy)ethoxy)ethyl)carbamate (15).—General procedure A, 56% yield. ¹H NMR (500 MHz, DMSO-*d*₆) δ 11.01 (s, 1H), 9.82 (s, 1H), 7.81 (d, *J* = 8.6 Hz, 1H), 7.50 (d, *J* = 10.3 Hz, 2H), 6.72 (t, *J* = 5.3 Hz, 1H), 5.15–5.08 (m, 1H), 4.44–4.27 (m, 2H), 3.70 (t, *J* = 6.3 Hz, 2H), 3.53–3.46 (m, 6H), 3.46–3.42 (m, 2H), 3.34 (s, 6H), 3.03 (q, *J* = 5.9 Hz, 2H), 2.59 (d, *J* = 6.3 Hz, 2H), 1.35 (s, 9H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 173.28, 171.49, 169.78, 168.25, 156.01, 134.09, 133.11, 129.09, 125.63, 119.53, 78.03, 70.15, 70.08, 69.93, 69.59, 67.04, 51.97, 46.88, 40.46, 40.30, 40.30, 40.13, 39.96, 39.80, 39.63, 39.46, 37.04, 31.65, 28.67, 23.12. HRMS (ESI-TOF) *m/z* calcd for C₂₇H₃₉N₄O₉ [M + H]⁺ 563.2717, found 563.2708.

tert-Butyl(24-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-24-oxo-3,6,9,12,15,18,21-heptaooxatetracosyl)carbamate (16).—General procedure A, 18% yield. ¹H NMR (500 MHz, D₂O) δ 7.61 (t, *J* = 8.5 Hz, 1H), 7.50 (dt, *J* = 15.2, 7.4 Hz, 2H), 5.05 (dd, *J* = 13.3, 5.3 Hz, 1H), 4.44–4.28 (m, 2H), 3.75 (t, *J* = 5.8 Hz, 2H), 3.65–3.35 (m, 26H), 3.10 (t, *J* = 5.3 Hz, 2H), 2.90–2.70 (m, 3H), 2.62 (t, *J* = 5.8 Hz, 2H), 2.48–2.32 (m, 2H), 2.24–2.09 (m, 2H), 1.27 (s, 9H). ¹³C NMR (126 MHz, D₂O) δ 175.70, 172.89, 172.22, 170.72, 158.07, 136.24, 131.84, 131.64, 129.52, 128.42, 121.59, 69.51, 69.46, 69.32, 66.57, 52.39, 47.58, 39.57, 36.11, 30.72, 27.60, 22.13. HRMS (ESI-TOF) *m/z* calcd for C₃₅H₅₄N₄O₁₃ [M + K]⁺ 777.3354, found 777.3316.

3-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)propenamide (18).—General procedure B, 100%. HRMS (ESI-TOF) *m/z* calcd for C₂₂H₃₁N₄O₇ [M + H]⁺ 463.2193, found 463.2177.

1-Amino-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-3,6,9,12,15,18,21-heptaooxa tetracosan-24-amide (19).—General procedure B, 100%. HRMS (ESI-TOF) *m/z* calcd for C₃₀H₄₆N₄O₁₁ [M + H]⁺ 639.3241, found 639.3239.

6-(((((((2S,3R,4S,5S)-5-(2-Amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(1-oxidaneyl)phosphoryl)amino)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)hexanamide (20).—General procedure C, 35% yield. ¹H NMR (500 MHz, DMSO-*d*₆)

δ 11.00 (s, 1H), 10.85 (s, 1H), 10.01 (s, 1H), 7.95 (s, 2H), 7.82 (d, $J = 6.5$ Hz, 1H), 7.50–7.41 (m, 2H), 5.69 (d, $J = 5.8$ Hz, 1H), 5.10 (dd, $J = 18.8, 6.4$ Hz, 1H), 4.54–4.47 (m, 1H), 4.43 (s, 1H), 4.41–4.38 (m, 1H), 4.35 (s, 1H), 4.31 (s, 1H), 4.19 (s, 1H), 4.01 (d, $J = 16.1$ Hz, 3H), 3.02 (s, 2H), 3.00–2.92 (m, 5H), 2.41–2.29 (m, 3H), 2.03–1.94 (m, 1H), 1.60–1.53 (m, 3H), 1.43 (s, 1H), 1.36–1.24 (m, 3H). **³¹P NMR** (202 MHz, DMSO- d_6) δ –2.48 (d, $J = 20.7$ Hz), –10.98 (d, $J = 20.8$ Hz). **HRMS (ESI-TOF)** m/z calcd for C₂₉H₃₆N₉O₁₄P₂ [M – H][–] 796.1857, found 796.1867.

3-(2-(2-(2-((((((2S,3R,4S,5S)-5-(2-Amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(11-oxidaneryl)phosphoryl)oxy)(hydroxy) phosphoryl)amino)ethoxy)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)propenamide (21).—General procedure C, 32% yield. **¹H NMR** (500 MHz, D₂O) δ 9.03 (d, $J = 10.8$ Hz, 1H), 7.67–7.50 (m, 3H), 5.97 (d, $J = 31.4$ Hz, 2H), 5.12 (d, $J = 13.3$ Hz, 2H), 4.61 (d, $J = 10.6$ Hz, 1H), 4.45 (d, $J = 17.1$ Hz, 2H), 4.37 (d, $J = 17.4$ Hz, 3H), 4.23 (d, $J = 10.8$ Hz, 1H), 3.84 (t, $J = 5.7$ Hz, 2H), 3.73–3.57 (m, 10H), 3.15 (t, $J = 6.4$ Hz, 4H), 3.12–3.06 (m, 5H), 2.72 (t, $J = 5.7$ Hz, 2H), 1.89–1.77 (m, 4H). **¹³C NMR** (126 MHz, D₂O) δ 175.67, 172.24, 170.62, 162.49, 160.43, 155.22, 154.75, 135.97, 131.75, 129.39, 128.14, 121.36, 119.64, 117.32, 115.00, 89.82, 83.67, 74.67, 74.50, 69.36, 66.52, 66.22, 55.24, 52.36, 47.49, 42.65, 38.95, 36.34, 34.88, 30.69, 24.88, 22.07; **³¹P NMR** (202 MHz, D₂O) δ –0.15, –0.19, –11.11, –11.21, –11.77, –23.59, –23.65. **HRMS (ESI-TOF)** m/z calcd for C₃₂H₄₂N₉O₁₇P₂ [M + NH₄]⁺ 886.2174, found 886.2175.

1-((((((2S,3R,4S,5S)-5-(2-Amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(11-oxidaneryl)phosphoryl)amino)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)-3,6,9,12,15,18,21-heptaaxatetracosan-24-amide (22).—General procedure C, 35% yield. **¹H NMR** (500 MHz, DMSO- d_6) δ 11.01 (s, 1H), 10.56 (s, 2H), 10.06 (s, 1H), 9.89 (s, 1H), 7.95–7.86 (m, 2H), 7.83 (d, $J = 7.2$ Hz, 1H), 7.76 (s, 1H), 7.45 (dd, $J = 18.2, 5.7$ Hz, 2H), 7.21 (s, 1H), 6.61 (d, $J = 45.8$ Hz, 4H), 5.96 (s, 3H), 5.65 (d, $J = 5.4$ Hz, 1H), 5.12 (dd, $J = 13.3, 5.0$ Hz, 1H), 4.78–4.69 (m, 1H), 4.65–4.56 (m, 2H), 4.39 (ddd, $J = 45.1, 25.5, 10.9$ Hz, 4H), 4.24 (s, 1H), 4.02–3.89 (m, 3H), 3.73–3.54 (m, 5H), 3.13 (s, 2H), 3.03–2.93 (m, 3H), 2.91 (s, 1H), 2.87 (s, 2H), 2.71 (s, 1H), 2.62 (d, $J = 5.0$ Hz, 3H), 2.52 (s, 2H), 2.32 (d, $J = 25.4$ Hz, 5H), 2.06 (d, $J = 6.2$ Hz, 2H), 1.86 (s, 2H), 1.59–1.50 (m, 2H), 1.09 (d, $J = 42.2$ Hz, 3H). **³¹P NMR** (202 MHz, DMSO- d_6) δ –1.69, –10.05. **HRMS (ESI-TOF)** m/z calcd for C₄₀H₅₈N₉O₂₁P₂ [M – H][–] 1062.3222, found 1062.3217.

2-Amino-7-benzyl-9-((2S,3S,4R,5S)-5-((((((6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)amino)-6-oxohexyl)amino)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy) methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-7-ium (23a).—General procedure D, 16% yield. **HRMS (ESI-TOF)** m/z calcd for C₃₆H₄₂N₉O₁₄P₂ [M – H][–] 886.2321, found 886.2361.

2-Amino-9-((2S,3S,4R,5S)-5-((((((6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-yl) amino)-6-oxohexyl)amino)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-7-(4-

fluorobenzyl)-6-oxo-6,9-dihydro-1H-purin-7-ium (23b).—General procedure D, 11% yield. **HRMS (ESI-TOF)** m/z calcd for $C_{36}H_{41}FN_9O_{14}P_2$ $[M - H]^-$ 904.2227, found 904.2212.

2-Amino-7-benzyl-9-((2S,3S,4R,5S)-5-((((((2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxo isoindolin-4-yl)amino)-3-oxopropoxy)ethoxy)ethoxy)ethyl)amino)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-7-ium (24a).—General procedure D, 20% yield. **HRMS (ESI-TOF)** m/z calcd for $C_{39}H_{48}N_9O_{17}P_2$ $[M - H]^-$ 976.2638, found 976.2677.

2-Amino-9-((2S,3S,4R,5S)-5-((((((2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-3-oxopropoxy)ethoxy)ethoxy)ethyl)amino)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-7-(4-fluorobenzyl)-6-oxo-6,9-dihydro-1H-purin-7-ium (24b).—General procedure D, 11% yield. **HRMS (ESI-TOF)** m/z calcd for $C_{39}H_{47}FN_9O_{17}P_2$ $[M - H]^-$ 994.2544, found 994.2543.

2-Amino-7-benzyl-9-((2R,3R,4S,5R)-5-((((((2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxo isoindolin-4-yl)amino)-24-oxo-3,6,9,12,15,18,21-heptaaxatetracosyl)amino)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-7-ium (25a).—General procedure D, 13% yield. **HRMS (ESI-TOF)** m/z calcd for $C_{47}H_{64}N_9O_{21}P_2$ $[M - H]^-$ 1152.3686, found 1152.3695.

2-Amino-9-((2R,3R,4S,5R)-5-((((((2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl) amino)-24-oxo-3,6,9,12,15,18,21-heptaaxatetracosyl)amino)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-7-(4-fluorobenzyl)-6-oxo-6,9-dihydro-1H-purin-7-ium (25b).—General procedure D, 9% yield. **HRMS (ESI-TOF)** m/z calcd for $C_{47}H_{63}FN_9O_{21}P_2$ $[M - H]^-$ 1170.3592, found 1170.3599.

tert-Butyl(6-(((2S)-1-((4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl) pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)carbamate (27).—General procedure A, 75% yield. **1H NMR** (500 MHz, Chloroform-*d*) δ 8.60 (s, 1H), 7.88 (d, J = 36.1 Hz, 1H), 7.17 (s, 1H), 6.57–6.43 (m, 1H), 4.69–4.58 (m, 2H), 4.52–4.39 (m, 3H), 4.24 (dd, J = 15.1, 5.2 Hz, 2H), 4.03 (d, J = 11.1 Hz, 1H), 3.62–3.48 (m, 1H), 3.01–2.91 (m, 2H), 2.86 (s, 1H), 2.79 (s, 1H), 2.42 (s, 3H), 2.39–2.20 (m, 2H), 2.10 (dd, J = 13.6, 7.3 Hz, 3H), 1.56–1.42 (m, 2H), 1.31 (s, 9H), 1.17 (d, J = 11.7 Hz, 3H), 0.85 (s, 9H). **^{13}C NMR** (126 MHz, Chloroform-*d*) δ 174.67, 174.11, 171.92, 170.91, 162.69, 156.06, 150.43, 148.27, 138.45, 138.12, 131.70, 130.79, 129.45, 128.02, 79.16, 77.27, 77.01, 76.76, 70.00, 58.89, 57.52, 56.97, 43.17, 40.33, 36.10, 34.94, 31.49, 29.57, 28.40, 26.39, 26.10, 25.16, 20.81, 15.91. **HRMS (ESI-TOF)** m/z calcd for $C_{33}H_{49}N_5O_6S$ $[M + H]^+$ 644.3482, found 644.3476.

(4R)-1-((S)-2-(6-Aminohexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl) pyrrolidine-2-carboxamide (28).—General procedure B, 90%. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.97 (s, 1H), 8.61 (s, 1H), 8.44 (s, 1H), 7.89 (d, *J* = 9.2 Hz, 1H), 7.45–7.32 (m, 5H), 4.53 (d, *J* = 9.3 Hz, 1H), 4.48–4.38 (m, 3H), 4.34 (s, 2H), 4.21 (dd, *J* = 15.8, 5.2 Hz, 2H), 3.65 (q, *J* = 12.2, 11.5 Hz, 3H), 2.72 (t, *J* = 7.4 Hz, 3H), 2.25 (dd, *J* = 14.1, 7.3 Hz, 2H), 2.12 (dt, *J* = 14.2, 7.1 Hz, 2H), 2.07–1.99 (m, 1H), 1.97–1.81 (m, 2H), 1.49 (dd, *J* = 17.0, 7.7 Hz, 6H), 1.27 (s, 3H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 172.41, 170.13, 166.85, 151.88, 148.14, 139.95, 131.61, 130.07, 129.30, 129.07, 128.52, 127.85, 69.31, 59.15, 56.81, 56.78, 42.10, 40.43, 40.35, 40.26, 40.09, 39.93, 39.76, 39.59, 39.43, 39.18, 38.42, 35.66, 35.27, 35.11, 27.60, 27.59, 26.83, 26.03, 25.90, 25.52, 25.39, 16.38. **HRMS (ESI-TOF)** *m/z* calcd for C₂₈H₄₁N₅O₄ [M + H]⁺ 544.2958, found 544.2939.

(4S)-1-((2S)-2-(6-((((((2S,3R,4S,5S)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(λ1-oxidaneyl) phosphoryl)amino)hexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (29).—General procedure C, 32% yield. ¹H NMR (500 MHz, DMSO-*d*₆) δ 9.10 (s, 1H), 8.97 (d, *J* = 4.3 Hz, 2H), 8.59–8.53 (m, 1H), 7.87 (d, *J* = 9.2 Hz, 2H), 7.48–7.29 (m, 7H), 6.61 (d, *J* = 52.9 Hz, 2H), 5.68 (d, *J* = 4.8 Hz, 1H), 4.58–4.15 (m, 9H), 3.69–3.57 (m, 3H), 3.49–3.23 (m, 8H), 2.43 (d, *J* = 3.0 Hz, 4H), 2.32–2.17 (m, 2H), 2.17–2.07 (m, 1H), 2.05 (s, 1H), 1.95–1.83 (m, 2H), 1.59–1.41 (m, 4H), 1.32–1.20 (m, 2H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 172.38, 170.13, 169.28, 152.02, 151.89, 148.33, 148.15, 139.95, 138.97, 131.60, 131.42, 130.63, 130.07, 129.40, 129.07, 128.25, 127.86, 69.87, 69.31, 59.15, 58.69, 56.79, 54.11, 42.51, 42.09, 40.46, 40.29, 40.12, 39.96, 39.79, 39.62, 39.46, 38.42, 35.68, 35.10, 27.24, 26.84, 26.00, 25.36, 16.40. **HRMS (ESI-TOF)** *m/z* calcd for C₃₈H₅₃N₁₀O₁₄P₂S [M+H]⁺ 969.3095, found 969.3085.

2-Amino-7-benzyl-9-((2S,3S,4R,5S)-3,4-dihydroxy-5-(((hydroxy((hydroxy((6-(((2S)-1-((4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbonyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)amino)phosphoryl)oxy)phosphoryl)oxy)methyl)tetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-7-ium (30a).—General procedure D, 11% yield. **HRMS (ESI-TOF)** *m/z* calcd for C₄₅H₅₉N₁₀O₁₄P₂S [M – H][–] 1057.3403, found 1057.3411.

2-Amino-9-((2S,3S,4R,5S)-3,4-dihydroxy-5-(((hydroxy((hydroxy((6-(((2S)-1-((4S)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbonyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-oxohexyl)amino)phosphoryl)oxy)phosphoryl)oxy)methyl)tetrahydrofuran-2-yl)-7-(4-fluorobenzyl)-6-oxo-6,9-dihydro-1H-purin-7-ium (30b).—General procedure D, 41% yield. **HRMS (ESI-TOF)** *m/z* calcd for C₄₅H₅₉FN₁₀O₁₄P₂S [M – H][–] 1075.3308, found 1075.3315.

((2R,3S,4R,5R)-5-(2-Amino-7-methyl-6-oxo-1,6-dihydro-9H-purin-7-ium-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl phosphate (m⁷GMP).—General procedure D, 75% yield. ¹H NMR (500 MHz, D₂O) δ 9.12 (s, 1H), 6.06 (d, *J* = 3.4 Hz, 1H),

4.67–4.63 (m, 1H), 4.45 (t, $J = 5.2$ Hz, 1H), 4.41–4.37 (m, 1H), 4.28–4.21 (m, 1H), 4.14–4.11 (m, 1H), 4.10 (s, 3H). **^{13}C NMR** (126 MHz, D_2O) δ 155.49, 154.99, 149.47, 136.43, 108.39, 89.67, 83.99, 74.67, 69.14, 63.28, 35.87. **^{31}P NMR** (202 MHz, D_2O) δ 0.12. **HRMS (ESI-TOF)** m/z calcd for $\text{C}_{11}\text{H}_{15}\text{N}_5\text{O}_8\text{P}$ $[\text{M} - \text{H}]^-$ 376.0664, found 376.0669.

4.7 Preparation of m^7GxP Agarose Resin

The synthesis was adapted from that of Edery et al. [52]. m^7GMP (synthesized; see below) or m^7GDP (Sigma) sodium salts was dissolved in water (10 mM final), and a solution of sodium periodate (1.0 equiv) in sodium acetate buffer (0.1 M, pH 6; 51 mM final) was added. The resulting mixture was agitated at 25 °C for 30 min protected from light. Adipic acid dihydrazide agarose (1 mL packed; Sigma) was washed with water (1× 20 mL) followed by sodium acetate buffer (1× 20 mL), and then resuspended in sodium acetate buffer (2 mL). To this slurry was added aniline (20 equiv) and the oxidized m^7GxP solution. The resin mixture was then shaken at 25 °C for 45 min before adding sodium cyanoborohydride (16 equiv). The mixture was agitated overnight at 4 °C. The resin was then washed with NaCl (1M; 5× 5 mL), equilibrated in buffer A (5 mL; 50 mM HEPES, pH 7, 200 mM KCl), and stored at 4 °C.

4.8 Cell Culture

HEK293 cells were grown in DMEM supplemented with 10% FBS and 1 mM Glutamine. MDA-MB-231 cells were grown in RPMI-1640 supplemented with 10% FBS and 1 mM Glutamine. K562 cells were grown in Iscove's Modified Dulbecco's Medium supplemented with 10% FBS and 1 mM Glutamine. Cells were grown at 37 °C with 5% CO_2 in a humidified incubator. All cell lines were authenticated by STR profiling and regularly tested for mycoplasma contamination

4.9 m^7G Cap Competition Assay and Western Blot

The cap competition assay was carried out as previously described (Yanagiya et al., 2012). Briefly, HEK293 cells were lysed in cap pull-down buffer (50 mM HEPES-KOH pH 7.5, 150 mM KCl, 1 mM EDTA, 2 mM DTT and 0.1% Tween 20) containing protease inhibitors and freeze-thawed thrice. Cell lysate was centrifuged at $20,000 \times g$ for 25 min. Total protein in the supernatant was measured using the BCA reagent (Thermo Scientific). 350 μg of total protein from the cell lysate was then incubated for 2 h at 4 °C with m^7GMP or m^7GDP agarose resin. The resin was washed 3× with cap pull-down buffer followed by 1× Tris Buffered Saline (TBS) and 1× Buffer A (50 mM HEPES-KOH pH 7.5, 150 mM KCl). The resin was then incubated with compounds (in Buffer A) overnight. The resin was again washed 1× with cap pull down buffer followed by 1× TBS and 1× water. Proteins were then eluted from the resin by boiling in 2× LDS sample buffer (10 min at 70 °C) resolved on a 4–12% Bis-Tris gel, and transferred to PVDF membrane in Towbin's Buffer. The membrane was blocked in 5% milk for 1 h at 25 °C, and then incubated with a primary antibody (overnight at 4 °C) and secondary antibody (1 h at 25 °C). Proteins were visualized by autoradiography. Anti-eIF4E antibody was purchased from Cell Signaling Technology (cat# 9742). Figures were formatted in Adobe Illustrator.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS:

We would like to thank Sydney Rosenblum for giving creative inputs while preparing the manuscript. This work was supported by the NIH (R01 CA202018 to A.L.G.).

REFERENCES:

- [1]. Sonenberg N, Hinnebusch AG, Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets, *Cell*. 136 (2009) 731–745. doi:10.1016/j.cell.2009.01.042. [PubMed: 19239892]
- [2]. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N, eIF4E – from translation to transformation, *Oncogene*. 23 (2004) 3172–3179. doi:10.1038/sj.onc.1207549. [PubMed: 15094766]
- [3]. Jia Y, Polunovsky V, Bitterman PB, Wagner CR, Cap-Dependent Translation Initiation Factor eIF4E: An Emerging Anticancer Drug Target, *Medicinal Research Reviews*. 32 (2012) 786–814. doi:10.1002/med.21260. [PubMed: 22495651]
- [4]. Sonenberg N, Gingras A-C, The mRNA 5' cap-binding protein eIF4E and control of cell growth, *Current Opinion in Cell Biology*. 10 (1998) 268–275. doi:10.1016/S0955-0674(98)80150-6. [PubMed: 9561852]
- [5]. Avdulov S, Li S, Van Michalek, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB, Polunovsky VA, Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells, *Cancer Cell*. 5 (2004) 553–563. doi:10.1016/j.ccr.2004.05.024. [PubMed: 15193258]
- [6]. Kerekatte V, Smiley K, Hu B, Smith A, Gelder F, Benedetti AD, The protooncogene/translation factor eIF4E: A survey of its expression in breast carcinomas, *International Journal of Cancer*. 64 (1995) 27–31. doi:10.1002/ijc.2910640107. [PubMed: 7665244]
- [7]. Nathan C-AO, Liu L, Li BD, Abreo FW, Nandy I, De Benedetti A, Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer, *Oncogene*. 15 (1997) 579–584. doi:10.1038/sj.onc.1201216. [PubMed: 9247311]
- [8]. Wang S, Rosenwald IB, Hutzler MJ, Pihan GA, Savas L, Chen J-J, Woda BA, Expression of the Eukaryotic Translation Initiation Factors 4E and 2 α in Non-Hodgkin's Lymphomas, *The American Journal of Pathology*. 155 (1999) 247–255. doi:10.1016/S0002-9440(10)65118-8. [PubMed: 10393856]
- [9]. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, Wang T, Sams L, Geeganage S, Douglass LE, Neubauer BL, Dean NM, Blanchard K, Shou J, Stancato LF, Carter JH, Marcusson EG, Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity, *J Clin Invest*. 117 (2007) 2638–2648. doi:10.1172/JCI32044. [PubMed: 17786246]
- [10]. Brown CJ, McNae I, Fischer PM, Walkinshaw MD, Crystallographic and Mass Spectrometric Characterisation of eIF4E with N7-alkylated Cap Derivatives, *Journal of Molecular Biology*. 372 (2007) 7–15. doi:10.1016/j.jmb.2007.06.033. [PubMed: 17631896]
- [11]. Fischer PM, Cap in hand: Targeting eIF4E, *Cell Cycle*. 8 (2009) 2535–2541. doi:10.4161/cc.8.16.9301. [PubMed: 19597330]
- [12]. Liu W, Zhao R, McFarland C, Kieft J, Niedzwiecka A, Jankowska-Anyszka M, Stepinski J, Darzynkiewicz E, Jones DNM, Davis RE, Structural Insights into Parasite eIF4E Binding Specificity for m7G and m2,2,7G mRNA Caps, *J. Biol. Chem* 284 (2009) 31336–31349. doi:10.1074/jbc.M109.049858. [PubMed: 19710013]
- [13]. Merrick WC, eIF4F: A Retrospective, *J. Biol. Chem* 290 (2015) 24091–24099. doi:10.1074/jbc.R115.675280. [PubMed: 26324716]

- [14]. Soukariéh F, Nowicki MW, Bastide A, Pöyry T, Jones C, Dudek K, Patwardhan G, Meullenet F, Oldham NJ, Walkinshaw MD, Willis AE, Fischer PM, Design of nucleotide-mimetic and non-nucleotide inhibitors of the translation initiation factor eIF4E: Synthesis, structural and functional characterisation, *European Journal of Medicinal Chemistry*. 124 (2016) 200–217. doi:10.1016/j.ejmech.2016.08.047. [PubMed: 27592390]
- [15]. Ziemniak M, Strenkowska M, Kowalska J, Jemielity J, Potential therapeutic applications of RNA cap analogs, *Future Medicinal Chemistry*. 5 (2013) 1141–1172. doi:10.4155/fmc.13.96. [PubMed: 23795970]
- [16]. Guimarães CRW, Kopecky DJ, Mihalic J, Shen S, Jeffries S, Thibault ST, Chen X, Walker N, Cardozo M, Thermodynamic Analysis of mRNA Cap Binding by the Human Initiation Factor eIF4E via Free Energy Perturbations, *J. Am. Chem. Soc* 131 (2009) 18139–18146. doi:10.1021/ja9064359. [PubMed: 19924990]
- [17]. Cai A, Jankowska-Anyszka M, Centers A, Chlebicka L, Stepinski J, Stolarski R, Darzynkiewicz E, Rhoads RE, Quantitative Assessment of mRNA Cap Analogues as Inhibitors of in Vitro Translation, *Biochemistry*. 38 (1999) 8538–8547. doi:10.1021/bi9830213. [PubMed: 10387101]
- [18]. Chen X, Kopecky DJ, Mihalic J, Jeffries S, Min X, Heath J, Deignan J, Lai S, Fu Z, Guimaraes C, Shen S, Li S, Johnstone S, Thibault S, Xu H, Cardozo M, Shen W, Walker N, Kayser F, Wang Z, Structure-Guided Design, Synthesis, and Evaluation of Guanine-Derived Inhibitors of the eIF4E mRNA–Cap Interaction, *J. Med. Chem* 55 (2012) 3837–3851. doi:10.1021/jm300037x. [PubMed: 22458568]
- [19]. Mehellou Y, Rattan HS, Balzarini J, The ProTide Prodrug Technology: From the Concept to the Clinic, *J. Med. Chem* 61 (2018) 2211–2226. doi:10.1021/acs.jmedchem.7b00734. [PubMed: 28792763]
- [20]. Pradere U, Garnier-Amblard EC, Coats SJ, Amblard F, Schinazi RF, Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs, *Chem. Rev* 114 (2014) 9154–9218. doi:10.1021/cr5002035. [PubMed: 25144792]
- [21]. Ghosh B, Benyumov AO, Ghosh P, Jia Y, Avdulov S, Dahlberg PS, Peterson M, Smith K, Polunovsky VA, Bitterman PB, Wagner CR, Nontoxic Chemical Interdiction of the Epithelial-to-Mesenchymal Transition by Targeting Cap-Dependent Translation, *ACS Chem. Biol* 4 (2009) 367–377. doi:10.1021/cb9000475. [PubMed: 19351181]
- [22]. Ohoka N, Shibata N, H. T and Naito M, Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy, *Current Cancer Drug Targets*. (2016). <http://www.eurekaselect.com/136884/article> (accessed November 20, 2018).
- [23]. Ottis P, Crews CM, Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy, *ACS Chem. Biol* 12 (2017) 892–898. doi:10.1021/acscchembio.6b01068. [PubMed: 28263557]
- [24]. Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K, Hines J, Winkler JD, Crew AP, Coleman K, Crews CM, Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4, *Chemistry & Biology*. 22 (2015) 755–763. doi:10.1016/j.chembiol.2015.05.009. [PubMed: 26051217]
- [25]. Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, Bradner JE, Phthalimide conjugation as a strategy for in vivo target protein degradation, *Science*. 348 (2015) 1376–1381. doi:10.1126/science.aab1433. [PubMed: 25999370]
- [26]. Lai AC, Crews CM, Induced protein degradation: an emerging drug discovery paradigm, *Nature Reviews Drug Discovery*. 16 (2017) 101–114. doi:10.1038/nrd.2016.211. [PubMed: 27885283]
- [27]. An S, Fu L, Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs, *EBioMedicine*. 36 (2018) 553–562. doi:10.1016/j.ebiom.2018.09.005. [PubMed: 30224312]
- [28]. Bondeson DP, Smith BE, Burslem GM, Buhimschi AD, Hines J, Jaime-Figueroa S, Wang J, Hamman BD, Ishchenko A, Crews CM, Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead, *Cell Chemical Biology*. 25 (2018) 78–87.e5. doi:10.1016/j.chembiol.2017.09.010. [PubMed: 29129718]
- [29]. Corson TW, Aberle N, Crews CM, Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One, *ACS Chem. Biol* 3 (2008) 677–692. doi:10.1021/cb8001792. [PubMed: 19112665]

- [30]. Galdeano C, Gadd MS, Soares P, Scaffidi S, Van Molle I, Birced I, Hewitt S, Dias DM, Ciulli A, Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities, *J. Med. Chem* 57 (2014) 8657–8663. doi:10.1021/jm5011258. [PubMed: 25166285]
- [31]. Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang C-Y, Zhao Y, McEachern D, Przybranowski S, Wen B, Sun D, Wang S, Discovery of a Small-Molecule Degradator of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression, *J. Med. Chem* 61 (2018) 462–481. doi: 10.1021/acs.jmedchem.6b01816. [PubMed: 28339196]
- [32]. Zengerle M, Chan K-H, Ciulli A, Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4, *ACS Chem. Biol* 10 (2015) 1770–1777. doi:10.1021/acschembio.5b00216. [PubMed: 26035625]
- [33]. Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AMK, Wang J, Chen X, Dong H, Siu K, Winkler JD, Crew AP, Crews CM, Coleman KG, PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer, *PNAS*. 113 (2016) 7124–7129. doi:10.1073/pnas.1521738113. [PubMed: 27274052]
- [34]. Schiedel M, Herp D, Hammelmann S, Swyter S, Lehotzky A, Robaa D, Oláh J, Ovádi J, Sippl W, Jung M, Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals), *J. Med. Chem* 61 (2018) 482–491. doi:10.1021/acs.jmedchem.6b01872. [PubMed: 28379698]
- [35]. Robb CM, Contreras JJ, Kour S, Taylor MA, Abid M, Sonawane YA, Zahid M, Murry DJ, Natarajan A, Rana S, Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC), *Chem. Commun* 53 (2017) 7577–7580. doi:10.1039/C7CC03879H.
- [36]. Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ, Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation, *PNAS*. 98 (2001) 8554–8559. doi:10.1073/pnas.141230798. [PubMed: 11438690]
- [37]. Lai AC, Toure M, Hellerschmied D, Salami J, Jaime-Figueroa S, Ko E, Hines J, Crews CM, Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL, *Angewandte Chemie International Edition*. 55 (2016) 807–810. doi:10.1002/anie.201507634. [PubMed: 26593377]
- [38]. Bondeson DP, Mares A, Smith IED, Ko E, Campos S, Miah AH, Mulholland KE, Routly N, Buckley DL, Gustafson JL, Zinn N, Grandi P, Shimamura S, Bergamini G, Faelth-Savitski M, Bantscheff M, Cox C, Gordon DA, Willard RR, Flanagan JJ, Casillas LN, Votta BJ, den Besten W, Famm K, Kruidenier L, Carter PS, Harling JD, Churcher I, Crews CM, Catalytic *in vivo* protein knockdown by small-molecule PROTACs, *Nature Chemical Biology*. 11 (2015) 611–617. doi:10.1038/nchembio.1858. [PubMed: 26075522]
- [39]. Jia Y, Chiu T-L, Amin EA, Polunovsky V, Bitterman PB, Wagner CR, Design, synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding antagonist Bn7-GMP, *European Journal of Medicinal Chemistry*. 45 (2010) 1304–1313. doi:10.1016/j.ejmech.2009.11.054. [PubMed: 20060622]
- [40]. Ghosh P, Park C, Peterson MS, Bitterman PB, Polunovsky VA, Wagner CR, Synthesis and evaluation of potential inhibitors of eIF4E cap binding to 7-methyl GTP, *Bioorganic & Medicinal Chemistry Letters*. 15 (2005) 2177–2180. doi:10.1016/j.bmcl.2005.01.080. [PubMed: 15808492]
- [41]. Li S, Jia Y, Jacobson B, McCauley J, Kratzke R, Bitterman PB, Wagner CR, Treatment of Breast and Lung Cancer Cells with a N-7 Benzyl Guanosine Monophosphate Tryptamine Phosphoramidate Pronucleotide (4Ei-1) Results in Chemosensitization to Gemcitabine and Induced eIF4E Proteasomal Degradation, *Molecular Pharmaceutics*. 10 (2013) 523–531. doi: 10.1021/mp300699d. [PubMed: 23289910]
- [42]. Othumpangat S, Kashon M, Joseph P, Eukaryotic Translation Initiation Factor 4E Is a Cellular Target for Toxicity and Death Due to Exposure to Cadmium Chloride, *J. Biol. Chem* 280 (2005) 25162–25169. doi:10.1074/jbc.M414303200. [PubMed: 15878868]
- [43]. Murata T, Shimotohno K, Ubiquitination and Proteasome-dependent Degradation of Human Eukaryotic Translation Initiation Factor 4E, *J. Biol. Chem* 281 (2006) 20788–20800. doi: 10.1074/jbc.M600563200. [PubMed: 16720573]

- [44]. Seo TW, Lee JS, Choi YN, Jeong DH, Lee SK, Yoo SJ, A novel function of cIAP1 as a mediator of CHIP-driven eIF4E regulation, *Scientific Reports*. 7 (2017) 9816. doi:10.1038/s41598-017-10358-2. [PubMed: 28852129]
- [45]. Marcotrigiano J, Gingras A-C, Sonenberg N, Burley SK, Cocystal Structure of the Messenger RNA 5' Cap-Binding Protein (eIF4E) Bound to 7-methyl-GDP, *Cell*. 89 (1997) 951–961. doi: 10.1016/S0092-8674(00)80280-9. [PubMed: 9200613]
- [46]. Buckley DL, Gustafson JL, Van Molle I, Roth AG, Tae HS, Gareiss PC, Jorgensen WL, Ciulli A, Crews CM, Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1 α , *Angewandte Chemie International Edition*. 51 (2012) 11463–11467. doi:10.1002/anie.201206231. [PubMed: 23065727]
- [47]. Ito T, Handa H, Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs, *International Journal of Hematology*. 104 (2016) 293–299. doi: 10.1007/s12185-016-2073-4. [PubMed: 27460676]
- [48]. Mori T, Ito T, Liu S, Ando H, Sakamoto S, Yamaguchi Y, Tokunaga E, Shibata N, Handa H, Hakoshima T, Structural basis of thalidomide enantiomer binding to cereblon, *Scientific Reports*. 8 (2018) 1294. doi:10.1038/s41598-018-19202-7. [PubMed: 29358579]
- [49]. Natarajan A, Moerke N, Fan Y-H, Chen H, Christ WJ, Wagner G, Halperin JA, Synthesis of fluorescein labeled 7-methylguanosinemonophosphate, *Bioorganic & Medicinal Chemistry Letters*. 14 (2004) 2657–2660. doi:10.1016/j.bmcl.2004.02.090. [PubMed: 15109672]
- [50]. Chou T-F, Baraniak J, Kaczmarek R, Zhou X, Cheng J, Ghosh B, Wagner CR, Phosphoramidate Pronucleotides: A Comparison of the Phosphoramidase Substrate Specificity of Human and *Escherichia coli* Histidine Triad Nucleotide Binding Proteins, *Mol. Pharmaceutics*. 4 (2007) 208–217. doi:10.1021/mp060070y.
- [51]. Shah R, Strom A, Zhou A, Maize KM, Finzel BC, Wagner CR, Design, Synthesis, and Characterization of Sulfamide and Sulfamate Nucleotidomimetic Inhibitors of hHint1, *ACS Med. Chem. Lett* 7 (2016) 780–784. doi:10.1021/acsmedchemlett.6b00169. [PubMed: 27563403]
- [52]. Edery I, Altmann M, Sonenberg N, High-level synthesis in *Escherichia coli* of functional cap-binding eukaryotic initiation factor eIF-4E and affinity purification using a simplified cap-analog resin, *Gene*. 74 (1988) 517–525. doi:10.1016/0378-1119(88)90184-9. [PubMed: 3246354]
- [53]. Xiong Y, Lu J, Hunter J, Li L, Scott D, Choi HG, Lim SM, Manandhar A, Gondi S, Sim T, Westover KD, Gray NS, Covalent Guanosine Mimetic Inhibitors of G12C KRAS, *ACS Med Chem Lett*. 8 (2017) 61–66. doi:10.1021/acsmedchemlett.6b00373. [PubMed: 28105276]
- [54]. Churcher I, Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?, *J. Med. Chem* 61 (2018) 444–452. doi:10.1021/acs.jmedchem.7b01272. [PubMed: 29144739]
- [55]. Boonstra J, Verkleij AJ, Regulation of enzyme activity in vivo is determined by its cellular localization, *Advances in Enzyme Regulation*. 44 (2004) 61–73. doi:10.1016/j.advenzreg.2003.11.008. [PubMed: 15581483]
- [56]. Yanagiya A, Suyama E, Adachi H, Svitkin YV, Aza-Blanc P, Imataka H, Mikami S, Martineau Y, Ronai ZA, Sonenberg N, Translational Homeostasis via the mRNA Cap-Binding Protein, eIF4E, *Molecular Cell*. 46 (2012) 847–858. doi:10.1016/j.molcel.2012.04.004. [PubMed: 22578813]

HIGHLIGHTS:

- New Bn⁷GMP- and Bn⁷GDP-based proteolysis targeting chimeras (PROTACs) were synthesized for the targeted degradation of eIF4E
- New m⁷GMP- and m⁷GDP-based cap competition assays were developed
- Discovery of Bn⁷GDP-based PROTACs with *in vitro* inhibitory activity of eIF4E-cap binding

Figure 1. eIF4E biological activity and structure. (A) Structure of the m⁷GpppX cap. (B) Crystal structure of eIF4E bound to the m⁷GpppX cap (PDB: 1EJ1). The key tryptophan residues for cap binding are highlighted, in addition to lysines close to the cap-binding pocket.

Figure 2.
Structures of previously reported m⁷G cap analogues [21].

Figure 3.
Cap-competition assay. (A) Assay overview. (B) Synthesis of $m^7\text{GxP}$ agarose resin.

Figure 4. Western blot analysis of eIF4E following the m⁷GMP cap competition assay. Immobilized eIF4E was treated with 500 μ M of m⁷GMP or a GMP- or Bn⁷GMP-based PROTAC. DMSO was used as a negative control.

Figure 5.

Western blot analysis of eIF4E following the m^7 GDP cap competition assay in HEK293 cell lysate. (A) Immobilized eIF4E was treated with 500 μ M of m^7 GDP or a GDP- or Bn 7 GDP-based PROTAC. DMSO was used as a negative control. (B) Dose-dependent inhibition by **23a**.

Figure 6. Western blot of total eIF4E following the treatment of K562 cells with Bn⁷GDP-based PROTACs. Actin was used as a loading control.

Scheme 1.
Synthesis of Bn⁷GMP-based lenalidomide conjugates.

Scheme 2.

Synthesis of sulfamate-containing Bn⁷GMP-based lenalidomide conjugates.

Scheme 3.

Synthesis of Bn⁷GDP-based lenalidomide conjugates.

Scheme 4.
Synthesis of Bn⁷GDP-based VHL conjugates.